Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F21%3A00546625" target="_blank" >RIV/68081707:_____/21:00546625 - isvavai.cz</a>

Alternative codes found

RIV/00159816:_____/21:00075037 RIV/00216224:14310/21:00122362

Result on the web

<a href="https://www.frontiersin.org/articles/10.3389/fphar.2021.740930/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fphar.2021.740930/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fphar.2021.740930" target="_blank" >10.3389/fphar.2021.740930</a>

Result language

angličtina

Original language name

Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study

Original language description

Benefit of thrombolytic therapy in patients with acute stroke, who are on anticoagulant treatment, is not well addressed. The aim of this study was to investigate whether apixaban can modify the thrombolytic efficacy of alteplase in vitro. Static and flow models and two variants of red blood cell (RBC) dominant clots, with and without apixaban, were used. Clots were prepared from the blood of healthy human donors and subsequently exposed to alteplase treatment. Apixaban and alteplase were used in clinically relevant concentrations. Clot lysis in the static model was determined both by clot weight and spectrophotometric determination of RBC release. Clot lysis in the flow model was determined by measuring recanalization time, clot length and spectrophotometric determination of RBC release. In the static model, clots without apixaban, compared to those with apixaban had alteplase-induced mass loss 54 +/- 8% vs. 53 +/- 8%, p = 1.00, RBC release 0.14 +/- 0.04 vs. 0.12 +/- 0.04, p = 0.14, respectively. Very similar results were obtained if plasma was used instead of physiological buffered saline as the incubation medium. In the flow model, clot lysis without apixaban, compared to those with apixaban was as follows: recanalization time 107 +/- 46 min vs. 127 +/- 31 min, p = 1.00, recanalization frequency 90 +/- 22% vs. 90 +/- 22%, p = 1.00, clot volume reduction 32 +/- 15% vs. 34 +/- 10%, p = 1.00, RBC release 0.029 +/- 0.007 vs. 0.022 +/- 0.007, p = 0.16, respectively. Apixaban had no positive effect on alteplase-induced thrombolysis in both the in vitro static and flow models. Our data support current clinical practice, such that thrombolysis is contraindicated in stroke treatment for patients who have been treated with anticoagulants.</p>

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

<a href="/en/project/EF16_026%2F0008451" target="_blank" >EF16_026/0008451: Engineering of new biomaterials and biopharmaceuticals for the diagnosis and treatment of the cerebrovascular and neurodegenerative diseases</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Pharmacology

ISSN

1663-9812

e-ISSN

1663-9812

Volume of the periodical

12

Issue of the periodical within the volume

SEP 15 2021

Country of publishing house

CH - SWITZERLAND

Number of pages

8

Pages from-to

740930

UT code for WoS article

000701295900001

EID of the result in the Scopus database

2-s2.0-85116001307